Fisher-Price Inclined Sleeper Recall Issued for Ultra-Lite Day & Night Play Yards

Amid continuing concerns about a growing number of infant deaths linked to inclined sleepers, a number of products have been pulled from the market due to the risk that infants may role over independently and become entrapped or suffocate.

A Fisher-Price inclined sleeper recall was announced by the U.S. Consumer Product Safety Commission (CPSC) this week, for more than 70,000 accessory units used with Ultra-Lite Day & Night Play yards.

Inclining infant sleepers are similar to bassinets, but are designed to elevate the baby’s head and torso. Inclining the infant during sleep has been shown to help prevent acid-reflux or congestion. However, the design has proven to be potentially deadly after babies are old enough to rollover on their own.

Did You Know? Millions of Philips CPAP Machines Recalled

Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.

Learn More

The recall includes inclined sleepers that were sold with the Fisher-Price Ultra-Lite Day & Night Play Yards, which were also equipped with changing station clutch accessories and a carry bag. The inclined sleepers marked with model numbers CBV60, CHP86, CHR06, CJK24, and DJD11 that were printed on a fabric label located inside of the inclined sleeper pad.

The products were manufactured by Fisher-Price of East Aurora, New York. They were distributed for sale at juvenile product stores and mass merchandisers nationwide from October 2014 through June 2019 for between $90 and $110.

Customers are being asked to stop using the inclined sleeper accessory immediately and to contact Fisher-Price at 800-432-5437 or visit their Recalls & Safety Alert page for additional information on how to receive a full refund.

Inclined Sleeper Warnings Follow Infant Deaths

The recall follows a slew of infant inclined sleeper products that have been deemed unsafe for infants.

Inclined sleeper safety concerns were disclosed to the public in April 2019, when the CPSC issued a Fisher-Price Rock’n Play warning, instructing consumers to stop placing their infants in the sleepers by three months old, or before they begin to show signs that they can roll over independently.

In response to the warning, the American Academy of Pediatrics (AAP) challenged the commissions warning indicating parents will not know the exact moment a child gains the ability to roll over, which may be too late and result in another infant death.

By the end of April, CSPC officials recalled 4.7 million Rock’n Play Sleepers and Kids II recalled all 694,000 of its inclined rocking sleepers. While there were 32 infant deaths reported at that time, at least 18 additional deaths have surfaced over the past few months, bringing the total number of deaths to approximately 50.

While some products have been recalled, and federal officials are considering a ban on inclined infant sleepers, the consumer watchdog group Consumer Reports urges parents and caregivers to stop using any and all rocking inclined sleepers.

ASTM International, the voluntary industry standards organization, is investigating the products’ standards and potential hazards. It expects that review to be completed by October 2019, at which time it will decide whether to recommend if sleepers should be eliminated from the market.

Since the recalls, Fischer-Price has been targeted by a number of inclined sleeper individual wrongful death lawsuits and also a class action lawsuit alleging the manufacturer knew or should have known about the risk of problems, yet delayed announcing a recall or warning, and knowingly allowed parents to continue purchasing life threatening sleeper devices.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Have Your Comments Reviewed by a Lawyer

Provide additional contact information if you want an attorney to review your comments and contact you about a potential case. This information will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Direct Filing of NEC Lawsuits Against Similac, Enfamil Manufacturers To Be Permitted in MDL
Direct Filing of NEC Lawsuits Against Similac, Enfamil Manufacturers To Be Permitted in MDL (Posted 6 days ago)

A federal judge plans to approve direct filing of future NEC lawsuits straight to the MDL court, streamlining the process for parents pursuing claims against the makers of Similac and Enfamil cow's milk-based formula.